alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)

A recent analysis is alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab).

These TNF inhibitors are wonder drugs for many patients with rheumatoid arthritis, Crohn's, and other autoimmune diseases.

But there's concern about an increased risk of serious infections and malignancies.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote